Table 1.
Baseline and clinical characteristics of the study population
| All participants (n=139) | |
|---|---|
|
| |
| Age (years, mean ± SD) | 38.6 ± 10.9 |
|
| |
| F:M (n) | 87:52 |
|
| |
| Disease duration (years, median, range) | 6 (1–20) |
|
| |
| EDSS (median, range) | 1 (0–4) |
|
| |
| Treatment (n) | |
| None | 2 |
| Interferon | 64 |
| Glatiramer Acetate | 34 |
| Natalizumab | 2 |
| Fingolimod | 26 |
| Other | 11 |
|
| |
| 6-SM levels (ng/mg creatinine, mean ± SEM) | |
| Summer | 19.8 ± 1.5 |
| Fall | 21.8 ± 1.6 |
| Winter | 24.7 ± 0.6 |
| Spring | 19.2 ± 1.7 |
|
| |
| Vitamin D levels (ng/mL) | |
| Summer | 27.8 ± 0.8 |
| Fall | 25.2 ± 0.1 |
| Winter | 21.7 ± 3.2 |
| Spring | 21.7 ± 3.3 |